viewBiocept Inc

Biocept wins US Patent for its liquid biopsy cancer testing technology; shares jump

The patent covers devices for the detection of cells of interest, including CTCs, that are shed into the bloodstream by solid tumors

Biocept Inc - Biocept Inc wins US Patent for its liquid biopsy technology that detects and isolates cancer biomarkers
The San Diego company has won more than 35 patents worldwide, stemming from its liquid biopsy technology and commercial-testing platforms

Biocept Inc (NASDAQ:BIOC), a developer of liquid biopsy tests that detect and isolate cancer biomarkers, announced Wednesday that it has been awarded a US Patent for its technology. 

Investors cheered the patent award, sending the stock up nearly 20% to $0.44 a share in New York.  

The newly issued patent --  DEVICES AND METHODS OF CELL CAPTURE AND ANALYSIS -- covers devices for the detection of cells of interest, including circulating tumor cells (CTCs), that are shed into the bloodstream by solid tumors where an antibody, or mixture of antibodies, and any solid surface are used for cell capture, detection, and analysis.  

The patent includes any biological sample type of interest and includes the use of single antibodies or cocktails of antibodies, Biocept said in a statement. 

READ: Biocept unveils latest liquid biopsy test to identify cancer-associated proteins

"The granting of this patent broadly expands Biocept's intellectual property estate for capturing and detecting cells of interest using antibodies, which combines nicely with our patented microchannel and cell staining platforms," said Lyle Arnold, Biocept's chief scientific officer.  

"This allowed patent also interfaces very well with our other patented technologies that include a blood collection tube, and ctDNA analysis platforms for aiding patient treatment decisions."

The company said the device claims covered by the patent broadly apply to the use of antibodies for the capture and detection of target cells of interest on any solid surface. This includes CTCs, as well as any other cell of interest. 

Capturing very rare cells

Combined with the company's patented microchannel and cell staining platform technologies, Biocept said it now has patented the capability to enable the capture of any cell of interest, including very rare cells, that may be present in blood and any other biological sample type.

"We continue to lead the way in innovation for liquid biopsy technology, and this latest patent demonstrates our leadership in creating new methodologies to identify potential cancer cells, or cells of any type for that matter,” said CEO Michael Nall.

“We are very proud of our innovations in the industry and look forward to sharing future applications for this patented technology to capture cellular targets in biological fluids, even when found in very small quantities."

Biocept, based in San Diego, has won more than 30 patents worldwide stemming from its liquid biopsy technology and commercial-testing platforms.

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

Quick facts: Biocept Inc

Price: 0.3564 USD

Market: NASDAQ
Market Cap: $38.74 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Biocept Inc named herein, including the promotion by the Company of Biocept Inc in any Content on the Site, the Company receives from said...



Full interview: Biocept reveals second contract for assay services after...

Biocept Inc (NASDAQ: BIOC) CEO Mike Nall says the San Diego-based biotech firm delivered revenue of $1.8 million during 4Q 2019, an increase of 108% over the same period last year, before it unveiled a second contract for its assay services with California independent physician...

1 week, 6 days ago

2 min read